type of report	**Current report**
number	4/2013
company	PHARMENA

Selection of a country of registration of 1-MNA dietary supplement

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13th April 2012) and the Company's announcement on the realisation of the Company's Strategy in the area of dietary supplement 1-MNA (published in current report no. 61/2012 of 17th September 2012), the Management Board of PHARMENA S.A. informs of its choice of an EU member state to carry out the registration process of dietary supplement based on 1-MNA as new foodstuff within the European procedure.

The selected EU member state is United Kingdom. With reference to the above, the Company plans to submit its application for registration of novel food ingredient pursuant to Art. 4 of Regulation (EC) no. 258/97 to Food Standards Agency; Novel Foods, Additives and Supplements Division in London, UK.

The Company intends to register the dietary supplement in 2013. Positive registration will open EU markets for the product.

The 1-MNA dietary supplement is an innovative product that has a capacity to influence the risk biomarkers of cardiovascular diseases and to stimulate the endogenous (natural) production of prostacyclin. Low levels of prostacyclin in human organism increase the risk of atherosclerosis. Studies have shown that the concentration of endogenous 1-MNA in human organism decreases with age. 1-MNA dietary supplement can complement 1-MNA deficiency in the organism and therefore stimulate the production of prostacyclin which reduces the risk of atherosclerosis development.

The European procedure is an application procedure compliant with the provisions of Art. 4 of Regulation (EC) no. 258/97 of the European Parliament and of the Council of 27th January 1997, which proves the safety and purposefulness of the use of novel food ingredient. Within this procedure, the entity responsible for placing on the Community market submits appropriate application to EU member state, where the new foodstuff is to be first placed on the market. An additional scientific assessment is performed at European level by European Food Safety Authority. Following the assessment, the European Commission, by relevant supervision authorities, grants permission for placing the new foodstuff on the market.

The information is made public due to the fact that introduction of innovative dietary supplement 1-MNA on the market may have a significant influence on the Company's financial situation in the next few years.

Legal basis: Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).

Representatives of the company:

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board